Article
Neonatal MSG reduces hypothalamic DA, beta-endorphin, and delays weight gain in genetically obese (A viable yellow/alpha) mice.
Pharmacology, biochemistry, and behavior - 1 Feb 1996
Caputo F A, Ali S F, Wolff G L, Scallet A C
Abstract excerpt
Neonatal treatment with monosodium glutamate (MSG) decreases proopiomelanocortin (POMC) peptides and results in obesity. The yellow mouse is a model of obesity induced by the viable yellow (Avy) gene at the agouti locus on Chromosome 2, which results in overproduction of a POMC receptor antagonist. Thus we hypothesized that MSG, when imposed on the genetically susceptible model, would alter the development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.